Skip to main content
. 2017 Feb 25;8(5):774–785. doi: 10.7150/jca.17550

Figure 6.

Figure 6

Assessment of 68Ga-NODAGA-PCA and 18FDG uptake in metastatic B16-F10 lesions 20 days after intravenous injection of tumor cells. Upper row: Representative axial CT (A), 18FDG-PET/CT (B) and 68Ga-NODAGA-PCA-PET/CT (C) images of the same tumor-bearing mouse. White arrows: metastatic B16-F10 lesions in the lung. Middle row: Representative axial CT (D), 18FDG-PET/CT (E) and 68Ga-NODAGA-PCA-PET/CT (F) images of a healthy control mouse. Lower row: metastatic B16-F10 lesions (white arrows) 20 days after tumor cell injection (G) and quantitative analysis of in vivo tracer uptake data (H) in B16-F10 tumors for 68Ga-NODAGA-PCA (n=5) and 18FDG (n=5). Significance level: p≤0.05 (*); p≤0.01 (**).